Regeneron Pharmaceuticals clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
34 trials changed in the last 30 days: 0 stopped, 9 with notable changes, 25 with minor changes only.
- Notable: NATRIX-BNP · REGN5381 · Heart Failure With Reduced Ejection Fraction Results posted: Nov 19, 2026
- Notable: Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors Recruitment opened
- Minor: ROXI-EVEREST · Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 66 → 84 locations
- Minor: LINKER-MM5 · Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 53 → 60 locations
- Minor: LINKER-AL2 · Linvoseltamab is Safe and Works · Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Trial sites expanded: 21 → 24 locations
- Minor: OLYMPIA-4 · Effective and Safe Odronextamab is Compared to Standard of Care · Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Study completion moved earlier from May 29, 2029 to May 29, 2028
- Notable: OPTIMA · Garetosmab Versus Placebo Administered Intravenously (IV) · Fibrodysplasia Ossificans Progressiva (FOP) Results posted: Nov 17, 2026
- Minor: COURAGE · If Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work · Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Trial completed
- Minor: NASHGEN-2 · Precision Medicine Approach Using Gene Silencing · a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition Enrollment closed, study ongoing
- Minor: Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults Trial sites expanded: 1 → 4 locations
- Notable: Health of Adult Participants From a Previous Study of a New Melanoma Treatment Primary and study completion pushed from Oct 10, 2029 to Oct 9, 2030
- Notable: Olatorepatide Versus Placebo · Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Recruitment opened
- Minor: See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Primary completion pushed from Jul 27, 2026 to Jan 15, 2027
- Notable: ALN-CIDEB · Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Enrollment increased: 150 → 360 participants
- Minor: Honey-B · Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy Primary and study completion pushed from Aug 21, 2026 to Nov 20, 2026
- Minor: ACCESS-1 · How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works · Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Trial completed
- Minor: LINKER-MM4 · Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works · Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Enrollment closed, study ongoing
- Minor: AURA-AD · REGN20423 in Healthy Adult Participants and Adult · Atopic Dermatitis Primary and study completion pushed from Jun 23, 2028 to Aug 14, 2028
- Minor: Ubamatamab Combination Therapy · Platinum-Resistant Ovarian Cancer Enrollment increased: 297 → 397 participants
- Minor: ROXI-ASPEN · REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants Trial sites expanded: 49 → 57 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-19 | NCT07947966 Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity | Phase 1 | Not Yet Recruiting |
| 2026-11-12 | NCT07933328 Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Phase 2 | Not Yet Recruiting |
| 2026-10-28 | NCT07901725 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone… | Phase 3 | Not Yet Recruiting |
| 2026-10-26 | NCT07896265 Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-21 | NCT07887750 REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or… | Phase 1/2 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 19 | |
| Phase 1/2 | 26 | |
| Phase 2 | 27 | |
| Phase 2/3 | 2 | |
| Phase 3 | 36 | |
| Phase 4 | 4 |
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 39
Multiple Myeloma (12) · Lung Cancer (11) · Non-Small Cell Lung Cancer (NSCLC) (11) · Obesity (10) · Non-Hodgkin Lymphoma (8) · Melanoma (7) · NASH / MASH (7) · Prostate Cancer (5) · Chronic Kidney Disease (4) · Follicular Lymphoma (4)
Get alerts when Regeneron Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.